Literature DB >> 6452931

[Mechanism of action of an anticonvulsant, sodium dipropylacetate].

S Simler, L Ciesielski, M Klein, S Gobaille, P Mandel.   

Abstract

The hypothesis that the brain GABA level increase which is induced by a sodium dipropyl acetate treatment arises either through inhibition of succinic semialdehyde dehydrogenase (SSADH), or through inhibition of GABA transaminase by succinic semialdehyde (SSA), has been considered. It appeared that in vivo brain GABA level increase cannot be attributed to SSADH inhibition, and that SSA is not a GABA precursor. It has been shown that SSA is neither in vivo nor in vitro a GABA-transaminase inhibitor. 4-hydroxybenzaldehyde, a potent SSADH inhibitor did not increase GABA level at a dosage which induces a 99% inhibition of SSADH.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6452931

Source DB:  PubMed          Journal:  C R Seances Soc Biol Fil        ISSN: 0037-9026


  3 in total

1.  Therapeutic efficacy of magnesium valproate in succinic semialdehyde dehydrogenase deficiency.

Authors:  Elena Vanadia; K Michael Gibson; Phillip L Pearl; Emanuele Trapolino; Salvatore Mangano; Francesca Vanadia
Journal:  JIMD Rep       Date:  2012-08-22

Review 2.  Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain.

Authors:  W Löscher
Journal:  Neurochem Res       Date:  1993-04       Impact factor: 3.996

Review 3.  Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism.

Authors:  P Malaspina; J-B Roullet; P L Pearl; G R Ainslie; K R Vogel; K M Gibson
Journal:  Neurochem Int       Date:  2016-06-14       Impact factor: 3.921

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.